A cancer drug can prevent neuronal cell death stroke
The role of a kind of killing cancer chemotherapeutic drugs used to prevent nerve cell death in stroke, the month of "natural - Neuroscience" is given a report on this conclusion.
The drug called ABT-737, can cause programmed cell death, which is often used in cancer therapy. Elizabeth Jonas and colleagues report that temporarily stops the blood supply in the brain, such as ischemia or stroke, under the control of the drug in certain neuronal cell death can be prevented. The drug seems to pass interference called deltaN-Bcl-xL pro-apoptotic proteins to play a role in the effect, deltaN-Bcl-xL in ischemia produced, which itself can cause programmed cell death.
Researchers unclear why this drug can kill tumor cells, but in the case of ischemia protects nerve cells. However, this study demonstrates the Bcl-xL protein can be used as a potential therapeutic target for stroke.
A cancer drug can prevent neuronal cell death stroke
ReplyDeleteThe role of a kind of killing cancer chemotherapeutic drugs used to prevent nerve cell death in stroke, the month of "natural - Neuroscience" is given a report on this conclusion.
The drug called ABT-737, can cause programmed cell death, which is often used in cancer therapy. Elizabeth Jonas and colleagues report that temporarily stops the blood supply in the brain, such as ischemia or stroke, under the control of the drug in certain neuronal cell death can be prevented. The drug seems to pass interference called deltaN-Bcl-xL pro-apoptotic proteins to play a role in the effect, deltaN-Bcl-xL in ischemia produced, which itself can cause programmed cell death.
Researchers unclear why this drug can kill tumor cells, but in the case of ischemia protects nerve cells. However, this study demonstrates the Bcl-xL protein can be used as a potential therapeutic target for stroke.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Lenvatinib
MGCD-265
Pazopanib Hydrochloride
Vatalanib
Cabozantinib S-malate
Ponatinib
CP-673451
KRN-633
Cabozantinib
Regorafenib hydrochloride